Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Maternal Cardiovascular Complications at the Time of Delivery and Subsequent Re-Hospitalization in the United States, 2010 to 2016.

Goyal N, Herrick JS, Son S, Metz TD, Shah RU.

Eur Heart J Qual Care Clin Outcomes. 2019 Oct 14. pii: qcz056. doi: 10.1093/ehjqcco/qcz056. [Epub ahead of print]

PMID:
31626292
2.

Reasons for cessation of clean intermittent catheterization after spinal cord injury: Results from the Neurogenic Bladder Research Group spinal cord injury registry.

Patel DP, Herrick JS, Stoffel JT, Elliott SP, Lenherr SM, Presson AP, Welk B, Jha A, Myers JB; Neurogenic Bladder Research Group (NBRG.org).

Neurourol Urodyn. 2019 Oct 2. doi: 10.1002/nau.24172. [Epub ahead of print]

PMID:
31578784
3.

The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy.

Case BC, Bress AP, Kolm P, Philip S, Herrick JS, Granowitz CB, Toth PP, Fan W, Wong ND, Hull M, Weintraub WS.

J Clin Lipidol. 2019 Sep - Oct;13(5):754-761. doi: 10.1016/j.jacl.2019.07.004. Epub 2019 Jul 20.

PMID:
31427271
4.

Angina Severity, Mortality, and Healthcare Utilization Among Veterans With Stable Angina.

Owlia M, Dodson JA, King JB, Derington CG, Herrick JS, Sedlis SP, Crook J, DuVall SL, LaFleur J, Nelson R, Patterson OV, Shah RU, Bress AP.

J Am Heart Assoc. 2019 Aug 6;8(15):e012811. doi: 10.1161/JAHA.119.012811. Epub 2019 Jul 31.

5.

Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation.

Greene T, Ying J, Vonesh EF, Tighiouart H, Levey AS, Coresh J, Herrick JS, Imai E, Jafar TH, Maes BD, Perrone RD, Del Vecchio L, Wetzels JFM, Heerspink HJL, Inker LA.

J Am Soc Nephrol. 2019 Sep;30(9):1756-1769. doi: 10.1681/ASN.2019010009. Epub 2019 Jul 10.

PMID:
31292198
6.

Association of Total Medication Burden With Intensive and Standard Blood Pressure Control and Clinical Outcomes: A Secondary Analysis of SPRINT.

Derington CG, Gums TH, Bress AP, Herrick JS, Greene TH, Moran AE, Weintraub WS, Kronish IM, Morisky DE, Trinkley KE, Saseen JJ, Reynolds K, Bates JT, Berlowitz DR, Chang TI, Chonchol M, Cushman WC, Foy CG, Herring CT, Katz LA, Krousel-Wood M, Pajewski NM, Tamariz L, King JB; SPRINT Research Group.

Hypertension. 2019 Jul 1:HYPERTENSIONAHA11912907. doi: 10.1161/HYPERTENSIONAHA.119.12907. [Epub ahead of print]

PMID:
31256717
7.

MicroRNA-messenger RNA interactions involving JAK-STAT signaling genes in colorectal cancer.

Mullany LE, Herrick JS, Sakoda LC, Samowitz W, Stevens JR, Wolff RK, Slattery ML.

Genes Cancer. 2018 May;9(5-6):232-246. doi: 10.18632/genesandcancer.177.

8.

Power in pairs: assessing the statistical value of paired samples in tests for differential expression.

Stevens JR, Herrick JS, Wolff RK, Slattery ML.

BMC Genomics. 2018 Dec 20;19(1):953. doi: 10.1186/s12864-018-5236-2.

9.

The TGFβ-signaling pathway and colorectal cancer: associations between dysregulated genes and miRNAs.

Pellatt AJ, Mullany LE, Herrick JS, Sakoda LC, Wolff RK, Samowitz WS, Slattery ML.

J Transl Med. 2018 Jul 9;16(1):191. doi: 10.1186/s12967-018-1566-8.

10.

The p53-signaling pathway and colorectal cancer: Interactions between downstream p53 target genes and miRNAs.

Slattery ML, Mullany LE, Wolff RK, Sakoda LC, Samowitz WS, Herrick JS.

Genomics. 2019 Jul;111(4):762-771. doi: 10.1016/j.ygeno.2018.05.006. Epub 2018 Jun 1.

11.

miRNA involvement in cell cycle regulation in colorectal cancer cases.

Mullany LE, Herrick JS, Sakoda LC, Samowitz W, Stevens JR, Wolff RK, Slattery ML.

Genes Cancer. 2018 Jan;9(1-2):53-65. doi: 10.18632/genesandcancer.167.

12.

The MAPK-Signaling Pathway in Colorectal Cancer: Dysregulated Genes and Their Association With MicroRNAs.

Slattery ML, Mullany LE, Sakoda LC, Wolff RK, Samowitz WS, Herrick JS.

Cancer Inform. 2018 Mar 26;17:1176935118766522. doi: 10.1177/1176935118766522. eCollection 2018.

13.

Mutation analysis of adenomas and carcinomas of the colon: Early and late drivers.

Wolff RK, Hoffman MD, Wolff EC, Herrick JS, Sakoda LC, Samowitz WS, Slattery ML.

Genes Chromosomes Cancer. 2018 Jul;57(7):366-376. doi: 10.1002/gcc.22539. Epub 2018 Apr 30.

14.

Dysregulated genes and miRNAs in the apoptosis pathway in colorectal cancer patients.

Slattery ML, Mullany LE, Sakoda LC, Wolff RK, Samowitz WS, Herrick JS.

Apoptosis. 2018 Apr;23(3-4):237-250. doi: 10.1007/s10495-018-1451-1.

15.

Expression of Wnt-signaling pathway genes and their associations with miRNAs in colorectal cancer.

Slattery ML, Mullany LE, Sakoda LC, Samowitz WS, Wolff RK, Stevens JR, Herrick JS.

Oncotarget. 2017 Dec 23;9(5):6075-6085. doi: 10.18632/oncotarget.23636. eCollection 2018 Jan 19.

16.

Infrequently expressed miRNAs in colorectal cancer tissue and tumor molecular phenotype.

Slattery ML, Lee FY, Pellatt AJ, Mullany LE, Stevens JR, Samowitz WS, Wolff RK, Herrick JS.

Mod Pathol. 2018 Jan;31(1):209. doi: 10.1038/modpathol.2017.118.

17.

MicroRNA-transcription factor interactions and their combined effect on target gene expression in colon cancer cases.

Mullany LE, Herrick JS, Wolff RK, Stevens JR, Samowitz W, Slattery ML.

Genes Chromosomes Cancer. 2018 Apr;57(4):192-202. doi: 10.1002/gcc.22520. Epub 2017 Dec 29.

18.

The NF-κB signalling pathway in colorectal cancer: associations between dysregulated gene and miRNA expression.

Slattery ML, Mullany LE, Sakoda L, Samowitz WS, Wolff RK, Stevens JR, Herrick JS.

J Cancer Res Clin Oncol. 2018 Feb;144(2):269-283. doi: 10.1007/s00432-017-2548-6. Epub 2017 Nov 29.

19.

Infrequently expressed miRNAs influence survival after diagnosis with colorectal cancer.

Slattery ML, Pellatt AJ, Lee FY, Herrick JS, Samowitz WS, Stevens JR, Wolff RK, Mullany LE.

Oncotarget. 2017 Aug 3;8(48):83845-83859. doi: 10.18632/oncotarget.19863. eCollection 2017 Oct 13.

20.

Identifying factors associated with the direction and significance of microRNA tumor-normal expression differences in colorectal cancer.

Stevens JR, Herrick JS, Wolff RK, Slattery ML.

BMC Cancer. 2017 Oct 30;17(1):707. doi: 10.1186/s12885-017-3690-x.

21.

The PI3K/AKT signaling pathway: Associations of miRNAs with dysregulated gene expression in colorectal cancer.

Slattery ML, Mullany LE, Sakoda LC, Wolff RK, Stevens JR, Samowitz WS, Herrick JS.

Mol Carcinog. 2018 Feb;57(2):243-261. doi: 10.1002/mc.22752. Epub 2017 Nov 19.

22.

An Assessment of Database-Validated microRNA Target Genes in Normal Colonic Mucosa: Implications for Pathway Analysis.

Slattery ML, Herrick JS, Stevens JR, Wolff RK, Mullany LE.

Cancer Inform. 2017 Jun 23;16:1176935117716405. doi: 10.1177/1176935117716405. eCollection 2017.

23.

The co-regulatory networks of tumor suppressor genes, oncogenes, and miRNAs in colorectal cancer.

Slattery ML, Herrick JS, Mullany LE, Samowitz WS, Sevens JR, Sakoda L, Wolff RK.

Genes Chromosomes Cancer. 2017 Nov;56(11):769-787. doi: 10.1002/gcc.22481. Epub 2017 Jul 30.

24.

Transcription factor-microRNA associations and their impact on colorectal cancer survival.

Mullany LE, Herrick JS, Wolff RK, Stevens JR, Samowitz W, Slattery ML.

Mol Carcinog. 2017 Nov;56(11):2512-2526. doi: 10.1002/mc.22698. Epub 2017 Aug 3.

25.

Infrequently expressed miRNAs in colorectal cancer tissue and tumor molecular phenotype.

Slattery ML, Lee FY, Pellatt AJ, Mullany LE, Stevens JR, Samowitz WS, Wolff RK, Herrick JS.

Mod Pathol. 2017 Aug;30(8):1152-1169. doi: 10.1038/modpathol.2017.38. Epub 2017 May 26. Erratum in: Mod Pathol. 2018 Jan;31(1):209.

26.

Alterations in microRNA expression associated with alcohol consumption in rectal cancer subjects.

Mullany LE, Herrick JS, Wolff RK, Stevens JR, Slattery ML.

Cancer Causes Control. 2017 Jun;28(6):545-555. doi: 10.1007/s10552-017-0882-2. Epub 2017 Mar 16.

27.

Genetic variants in the TGFβ-signaling pathway influence expression of miRNAs in colon and rectal normal mucosa and tumor tissue.

Slattery ML, Trivellas A, Pellatt AJ, Mullany LE, Stevens JR, Wolff RK, Herrick JS.

Oncotarget. 2017 Mar 7;8(10):16765-16783. doi: 10.18632/oncotarget.14508.

28.

Diet and lifestyle factors associated with miRNA expression in colorectal tissue.

Slattery ML, Herrick JS, Mullany LE, Stevens JR, Wolff RK.

Pharmgenomics Pers Med. 2016 Dec 20;10:1-16. doi: 10.2147/PGPM.S117796. eCollection 2017.

29.

The miRNA landscape of colorectal polyps.

Slattery ML, Herrick JS, Wolff RK, Mullany LE, Stevens JR, Samowitz W.

Genes Chromosomes Cancer. 2017 May;56(5):347-353. doi: 10.1002/gcc.22436. Epub 2017 Feb 1.

30.

Single nucleotide polymorphisms within MicroRNAs, MicroRNA targets, and MicroRNA biogenesis genes and their impact on colorectal cancer survival.

Mullany LE, Herrick JS, Wolff RK, Slattery ML.

Genes Chromosomes Cancer. 2017 Apr;56(4):285-295. doi: 10.1002/gcc.22434. Epub 2017 Jan 25.

31.

Association of cigarette smoking and microRNA expression in rectal cancer: Insight into tumor phenotype.

Mullany LE, Herrick JS, Wolff RK, Stevens JR, Slattery ML.

Cancer Epidemiol. 2016 Dec;45:98-107. doi: 10.1016/j.canep.2016.10.011. Epub 2016 Oct 22.

32.

Telomere Length, TERT, and miRNA Expression.

Slattery ML, Herrick JS, Pellatt AJ, Wolff RK, Mullany LE.

PLoS One. 2016 Sep 14;11(9):e0162077. doi: 10.1371/journal.pone.0162077. eCollection 2016.

33.

Site-specific associations between miRNA expression and survival in colorectal cancer cases.

Slattery ML, Herrick JS, Pellatt DF, Mullany LE, Stevens JR, Wolff E, Hoffman MD, Wolff RK, Samowitz W.

Oncotarget. 2016 Sep 13;7(37):60193-60205. doi: 10.18632/oncotarget.11173.

34.

Colorectal tumor molecular phenotype and miRNA: expression profiles and prognosis.

Slattery ML, Herrick JS, Mullany LE, Wolff E, Hoffman MD, Pellatt DF, Stevens JR, Wolff RK.

Mod Pathol. 2016 Aug;29(8):915-27. doi: 10.1038/modpathol.2016.73. Epub 2016 May 20.

35.

MicroRNA Seed Region Length Impact on Target Messenger RNA Expression and Survival in Colorectal Cancer.

Mullany LE, Herrick JS, Wolff RK, Slattery ML.

PLoS One. 2016 Apr 28;11(4):e0154177. doi: 10.1371/journal.pone.0154177. eCollection 2016.

36.

Impact of polymorphisms in microRNA biogenesis genes on colon cancer risk and microRNA expression levels: a population-based, case-control study.

Mullany LE, Herrick JS, Wolff RK, Buas MF, Slattery ML.

BMC Med Genomics. 2016 Apr 23;9(1):21. doi: 10.1186/s12920-016-0181-x.

37.

Expression Profiles of miRNA Subsets Distinguish Human Colorectal Carcinoma and Normal Colonic Mucosa.

Pellatt DF, Stevens JR, Wolff RK, Mullany LE, Herrick JS, Samowitz W, Slattery ML.

Clin Transl Gastroenterol. 2016 Mar 10;7:e152. doi: 10.1038/ctg.2016.11.

38.

MicroRNA profiles in colorectal carcinomas, adenomas and normal colonic mucosa: variations in miRNA expression and disease progression.

Slattery ML, Herrick JS, Pellatt DF, Stevens JR, Mullany LE, Wolff E, Hoffman MD, Samowitz WS, Wolff RK.

Carcinogenesis. 2016 Mar;37(3):245-261. doi: 10.1093/carcin/bgv249. Epub 2016 Jan 6.

39.

SNP Regulation of microRNA Expression and Subsequent Colon Cancer Risk.

Mullany LE, Wolff RK, Herrick JS, Buas MF, Slattery ML.

PLoS One. 2015 Dec 2;10(12):e0143894. doi: 10.1371/journal.pone.0143894. eCollection 2015.

40.

Gene expression in colon cancer: A focus on tumor site and molecular phenotype.

Slattery ML, Pellatt DF, Mullany LE, Wolff RK, Herrick JS.

Genes Chromosomes Cancer. 2015 Sep;54(9):527-41. doi: 10.1002/gcc.22265. Epub 2015 Jul 14.

41.

Improved survival among colon cancer patients with increased differentially expressed pathways.

Slattery ML, Herrick JS, Mullany LE, Gertz J, Wolff RK.

BMC Med. 2015 Apr 8;13:75. doi: 10.1186/s12916-015-0292-9.

42.

An evaluation and replication of miRNAs with disease stage and colorectal cancer-specific mortality.

Slattery ML, Herrick JS, Mullany LE, Valeri N, Stevens J, Caan BJ, Samowitz W, Wolff RK.

Int J Cancer. 2015 Jul 15;137(2):428-38. doi: 10.1002/ijc.29384. Epub 2014 Dec 16.

43.

Genetic variants in interleukin genes are associated with breast cancer risk and survival in a genetically admixed population: the Breast Cancer Health Disparities Study.

Slattery ML, Herrick JS, Torres-Mejia G, John EM, Giuliano AR, Hines LM, Stern MC, Baumgartner KB, Presson AP, Wolff RK.

Carcinogenesis. 2014 Aug;35(8):1750-9. doi: 10.1093/carcin/bgu078. Epub 2014 Mar 26.

44.

Telomere length, telomere-related genes, and breast cancer risk: the breast cancer health disparities study.

Pellatt AJ, Wolff RK, Torres-Mejia G, John EM, Herrick JS, Lundgreen A, Baumgartner KB, Giuliano AR, Hines LM, Fejerman L, Cawthon R, Slattery ML.

Genes Chromosomes Cancer. 2013 Jul;52(7):595-609. doi: 10.1002/gcc.22056. Epub 2013 Apr 30.

45.

Genetic variation in bone morphogenetic proteins and breast cancer risk in hispanic and non-hispanic white women: The breast cancer health disparities study.

Slattery ML, John EM, Torres-Mejia G, Herrick JS, Giuliano AR, Baumgartner KB, Hines LM, Wolff RK.

Int J Cancer. 2013 Jun 15;132(12):2928-39. doi: 10.1002/ijc.27960. Epub 2012 Dec 13.

46.

Interleukin genes and associations with colon and rectal cancer risk and overall survival.

Bondurant KL, Lundgreen A, Herrick JS, Kadlubar S, Wolff RK, Slattery ML.

Int J Cancer. 2013 Feb 15;132(4):905-15. doi: 10.1002/ijc.27660. Epub 2012 Jun 26.

47.

Genetic variation in genes involved in hormones, inflammation and energetic factors and breast cancer risk in an admixed population.

Slattery ML, John EM, Torres-Mejia G, Lundgreen A, Herrick JS, Baumgartner KB, Hines LM, Stern MC, Wolff RK.

Carcinogenesis. 2012 Aug;33(8):1512-21. doi: 10.1093/carcin/bgs163. Epub 2012 May 4.

48.

Genetic variation in the transforming growth factor-β-signaling pathway, lifestyle factors, and risk of colon or rectal cancer.

Slattery ML, Lundgreen A, Wolff RK, Herrick JS, Caan BJ.

Dis Colon Rectum. 2012 May;55(5):532-40. doi: 10.1097/DCR.0b013e31824b5feb.

49.

Diet and colorectal cancer: analysis of a candidate pathway using SNPS, haplotypes, and multi-gene assessment.

Slattery ML, Lundgreen A, Herrick JS, Caan BJ, Potter JD, Wolff RK.

Nutr Cancer. 2011 Nov;63(8):1226-34. doi: 10.1080/01635581.2011.607545. Epub 2011 Oct 14.

50.

Toll-like receptor genes and their association with colon and rectal cancer development and prognosis.

Slattery ML, Herrick JS, Bondurant KL, Wolff RK.

Int J Cancer. 2012 Jun 15;130(12):2974-80. doi: 10.1002/ijc.26314. Epub 2011 Oct 20.

Supplemental Content

Loading ...
Support Center